Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Perjeta or Perjeta-Herceptin Combo Pack Pertuzumab Neoadjuvant Breast Cancer Do not reimburse Complete
Perjeta-Herceptin Combo Pack Pertuzumab-Trastuzumab Combo Pack Early Breast Cancer Do not reimburse Complete
Perseris risperidone Schizophrenia, adults Reimburse with clinical criteria and/or conditions Complete
Pheburane Sodium phenylbutyrate Urea cycle disorders List Complete
Picato Ingenol mebutate Actinic keratosis N/A Complete
Picato Ingenol mebutate Actinic keratosis Do not list Complete
Pifeltro doravirine HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Piqray alpelisib Advanced or Metastatic Breast Cancer Do not reimburse Complete
Plegridy Peginterferon beta-1a Multiple sclerosis, relapsing-remitting List with criteria/condition Complete
Pluvicto lutetium vipivotide tetraxetan Metastatic castration-resistant prostate cancer Reimburse with clinical criteria and/or conditions Complete